DLL3 and small cell lung carcinoma: Therefore, against the high expression of DLL3, it was found that Tarlatamab (AMG 757) could cause tumors to regress to different degrees by combining DLL3 and CD3 on T cells, which provides a new direction for targeted immunotherapy for SCLC (116).